MariTide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions for clinical trial formulations managed per protocol. Antibody-based therapeutics typically require refrigerated storage (2-8 C).
Protocol Quick-Reference
Chronic weight management
Dosing
Amount
Monthly SC dose (specific mg not fully disclosed)
Frequency
Monthly or less frequent
Duration
52 weeks (Phase 2); 72 weeks (Phase 3)
Administration
Route
SCSchedule
Monthly or less frequent
Timing
Delivered via autoinjector device. Half-life of approximately 21 days supports monthly dosing. Dose escalation likely used per GLP-1 class standard.
Cycle
Duration
52-72 weeks (ongoing treatment expected)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
HbA1c
When: Baseline and every 12 weeks
Why: Monitor glycemic control (especially in T2D cohort)
Fasting glucose and insulin
When: Baseline and 12 weeks
Why: Assess metabolic response
Lipid panel
When: Baseline and 12 weeks
Why: Monitor metabolic parameters
Liver function tests (ALT, AST)
When: Baseline and 12 weeks
Why: Monitor hepatic function
๐ก Key Considerations
- โInvestigational: MariTide is not FDA-approved and is available only in clinical trials
- โMonthly dosing is a significant convenience advantage over weekly GLP-1 agonists
- โNovel antibody-peptide conjugate format distinct from standard peptide drugs
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Monthly or less frequent (subcutaneous) | 52 weeks in Phase 2 | No weight loss plateau at 52 weeks. HbA1c reduction up to 2.2 percentage points in T2D cohort. Phase 3 informed by these results. | ||
| Subcutaneous (dosing intervals evaluated) | Variable | Published in Nature Metabolism. Confirmed acceptable safety, tolerability, and dose-dependent pharmacodynamic effects. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Not applicable - MariTide is provided as a ready-to-use subcutaneous injection in an autoinjector device
Recommended Injection Sites
- โAbdomen
- โThigh
- โUpper arm
๐งStorage Requirements
Storage conditions for clinical trial formulations managed per protocol. Antibody-based therapeutics typically require refrigerated storage (2-8 C).
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Disclaimer#
MariTide is an investigational drug not yet approved by any regulatory authority. All dosing information is derived from clinical trial protocols and published results. MariTide should only be used within approved clinical trials.
Clinical Trial Dosing#
Phase 2 Trial (52 Weeks)#
The Phase 2 trial enrolled 592 participants in two cohorts across 11 dose groups:
Cohort 1: Obesity without T2D
- Multiple monthly SC doses evaluated
- Highest dose achieved ~20% weight loss at 52 weeks
- No weight loss plateau at 52 weeks
- Dose-dependent response
Cohort 2: Obesity with T2D
- Monthly SC dosing evaluated
- Achieved ~17% weight loss at 52 weeks
- HbA1c reduction up to 2.2 percentage points
- No weight loss plateau
Phase 1 Trial#
The Phase 1 trial published in Nature Metabolism confirmed:
- Dose-dependent weight loss
- Acceptable safety and tolerability
- Half-life of ~21 days supporting monthly dosing
Monthly Dosing Advantage#
MariTide's most distinctive practical feature is its monthly or less frequent dosing schedule. This compares favorably to current approved therapies:
| Therapy | Dosing Frequency | Administration |
|---|---|---|
| MariTide | Monthly or less | SC autoinjector |
| Semaglutide (Wegovy) | Weekly | SC injection |
| Tirzepatide (Zepbound) | Weekly | SC injection |
| Liraglutide (Saxenda) | Daily | SC injection |
| Oral semaglutide | Daily | Oral tablet |
Monthly dosing may improve adherence and patient convenience compared to weekly injections, and is enabled by MariTide's ~21-day half-life from its antibody component.
Administration#
Subcutaneous Injection#
- Monthly or less frequent subcutaneous injection
- Expected delivery via patient-friendly autoinjector device
- Standard SC injection sites (abdomen, thigh, upper arm)
- Single-injection administration per dose
Dose Escalation#
Like other GLP-1-based therapies, MariTide likely uses a dose escalation approach. Specific escalation schedules from the Phase 2 trial have not been fully disclosed publicly.
Phase 3 MARITIME Program#
The Phase 3 MARITIME program evaluates MariTide over 72 weeks in chronic weight management. Dosing regimens for Phase 3 were informed by Phase 2 and Phase 1 PK-LDI data. Specific Phase 3 doses have not been fully disclosed.
Dosing Context#
MariTide belongs to the Metabolic category of research peptides. Dosing protocols for MariTide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for MariTide:
undefined#
Dose: undefined
Frequency: Monthly or less frequent (subcutaneous)
Duration: 52 weeks in Phase 2
No weight loss plateau at 52 weeks. HbA1c reduction up to 2.2 percentage points in T2D cohort. Phase 3 informed by these results.
undefined#
Dose: undefined
Frequency: Subcutaneous (dosing intervals evaluated)
Duration: Variable
Published in Nature Metabolism. Confirmed acceptable safety, tolerability, and dose-dependent pharmacodynamic effects.
Reconstitution and Preparation#
Not applicable - MariTide is provided as a ready-to-use subcutaneous injection in an autoinjector device
Injection Sites#
Recommended injection sites for MariTide include:
- Abdomen
- Thigh
- Upper arm
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Storage conditions for clinical trial formulations managed per protocol. Antibody-based therapeutics typically require refrigerated storage (2-8 C).
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About MariTide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.